GlycoScore will drastically reduce over-diagnosis so that only men with a high risk of prostate cancer need to undergo biopsies. This will improve care for patients and also provide cost savings for health care systems. In addition, GlycoScore will also speed up diagnosis, identify aggressive cancers sooner and potentially save lives.